Clover vaccines use Dynavax adjunct so it will probably not get a big order from China. But if the trial is successful, then it is possible that it would still be included in the national vaccine rollout. Clover is also position itself as an export focused vaccine. I think one issue for Clover is that it requires 3 doses like Zhifei subunit vaccines.
Clover's Phase III trials uses only 2 doses, 21 days apart. Clover will likely be export focused, but I would still expect demand to be at least close to a billion doses, if anything more to boost the CoronaVac/Sinopharm/Cansino shots which have been exported so far. Its going for approval with China, Europe, and WHO simultaneously.
I think the chinese second generation will be mostly booster shots, since I dont think many of us were expecting 50% of global vaccine production to have come from china even at Q3.